3 results
Primary:• To prove the superiority of a 12-week add-on treatment with 3.2 g/daygastro-resistant phosphatidylcholine granules (LT-02) in at least one of twodifferent dosing regimens versus LT-02 placebo for the induction ofremission in patients with…
Primairy Objective* To test whether 5-ASA reduces the occurrence of colonic benign or malignant neoplasia compared to placebo in Lynch syndrome (LS) patients as detected by any colonoscopy until the end of study.Secondary Objectives* To test wheter…
The primary objective is to compare doxorubicin plus olaratumab versus doxorubicin plus placebo with respect to OS in patients with advanced or metastatic soft tissue sarcoma (STS) or advanced or metastatic leiomyosarcoma (LMS), not amenable to…